TY - JOUR
T1 - Biologics for the treatment of Juvenile Idiopathic Arthritis
AU - Poddighe, Dimitri
AU - Romano, Micol
AU - Gattinara, Maurizio
AU - Gerloni, Valeria
N1 - Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
PY - 2018/5/21
Y1 - 2018/5/21
N2 - Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.
AB - Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.
U2 - 10.2174/0929867325666180522085716
DO - 10.2174/0929867325666180522085716
M3 - Article
C2 - 29788871
SN - 0929-8673
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
ER -